Septic Shock News and Research

RSS

Template for COVID-19 management in a rural health system

As the COVID-19 pandemic continues to challenge existing health networks, a new study published on the preprint server medRxiv in October 2020 reports on a strategy to address existing health care disparities in rural and urban areas of the USA. This should draw attention to the need for more such systems to ensure proper rural healthcare in the current and future pandemics.

20 Oct 2020

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.

6 Oct 2020

Shorter time from COVID-19 symptom onset to hospitalization linked to disease severity, death

New research presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID, held online) shows that a shorter time from symptom onset to hospitalization is associated with more serious disease and death in patients with COVID-19.

26 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

Earlier treatment with steroids reduces adverse outcomes in patients with septic shock

Some critically ill patients with septic shock need medications called vasopressors to correct dangerously low blood pressure.

14 Sep 2020

COVID-19 in pregnancy doubles odds of preterm delivery

The COVID-19 pandemic is continuing to cause huge social, economic, and health-related costs throughout the world, especially in Spain. Clinicians are still coming to terms with the range of health conditions wrought by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A new study published on the preprint server medRxiv* in September 2020 shows that this infection results in fetal and maternal complications.

9 Sep 2020

COVID-19 is not characterized by a cytokine storm, shows study

Does the COVID-19 cytokine storm exist? Inflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known as "cytokine storm", it can cause harm to the patient.

5 Sep 2020

Surgical patients with low health literacy more likely to experience postoperative infection

Surgical patients are more likely to experience a postoperative infection if they have low health literacy, which is a limited capacity to understand and act on health information, according to results of a new study presented at the American College of Surgeons 2020 Quality and Safety Conference VIRTUAL.

24 Aug 2020

Photonics-based device could help COVID-19 patients with adequate treatments

Few could have foreseen the considerable impact that SARS-CoV-2 has had so far and is still having worldwide. Numbers continue to escalate and the complexity of the COVID-19 symptoms have hindered all efforts to optimize its treatment.

3 Aug 2020

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin. Blood levels of bio-ADM® reflect in real-time the functional status of the endothelium, the inner cell sheet of blood vessels.

24 Jul 2020

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

22 Jul 2020

Clots, COVID-19 and survival

The novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes COVID-19 disease, was first reported in Wuhan, Hubei Province of China in late December 2019. Since then, it has infected a large population across the world with the current number of SARS-CoV-2 infections standing at over 13 million and COVID-19 disease having killed over 571,000 individuals.

13 Jul 2020

Oral hygiene and severity of COVID-19 – the connection

Their study titled, “Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?” was published in the latest issue of the journal British Dental Journal.

30 Jun 2020

COVID-19 plasma therapy safe and improves survival, says large study

Researchers working on COVID-19 therapy with plasma from convalescent patients have found that it is safe and effective and improves the chances of survival among those who are severely ill. The new study titled, “Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients,” is published as a preprint for the journal Mayo Clinic Proceedings.

20 Jun 2020

Novel biomarkers required to triage and monitor severely ill COVID-19 patients

Diagnostics company SphingoTec GmbH ("sphingotec") announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec's diagnostic solutions for acute and critical care in supporting the triage, diagnosis, and management of severely ill COVID-19 patients.

18 Jun 2020

Effect of human genes on severity and infectivity of SARS-CoV-2

Now, a new paper published on the preprint server medRxiv* reports the results of an analysis of the association between the genetic variants in the patients and the clinical progression of the disease. The study included 332 patients hospitalized with COVID-19 in a single-center, with widely varying laboratory and clinical features. There were 25, 12, and 17 patients with asymptomatic, mild, and critical disease.

14 Jun 2020

Antihypotensive agent for sepsis disrupts the immune system, increases susceptibility to infections

Patients who go into shock caused by sepsis (septic shock) are treated with the antihypotensive agent norepinephrine.

11 Jun 2020

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020

Molecular signatures can predict outcome of sepsis patients based on their immune response

Scientists have identified molecular signatures in the immune component of the blood which indicate how patients in intensive care with sepsis, septic shock and systemic inflammatory response syndrome are likely to respond to the conditions.

28 May 2020

Novel testing system predicts outcomes in patients with sepsis

More than 1.7 million Americans develop sepsis each year, and more than 270,000 die from it. The condition--which happens when the body has an extreme response to a bacterial or viral infection, causing a chain reaction that can lead to organ failure and death--has few strategies for treatment.

26 May 2020